## SYNTHETIC APPROACH TO THE TOTAL SYNTHESIS OF FUMITREMORGINS II SYNTHESIS OF OPTICALLY ACTIVE PENTACYCLIC INTERMEDIATES AND THEIR DEHYDROGENATION

Masako Nakagawa,<sup>\*</sup> Hiroshi Fukushima, Tomohiko Kawate, Mitsuya Hongu, Shin-ichi Kodato, Teruaki Une, Mikio Taniguchi, and Tohru Hino<sup>\*</sup> Faculty of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Chiba-shi, 260, Japan

Summary : Optically active pentacycles( 13-18 ) were synthesized from L- and D-tryptophans, two of which ( 13 and 15 ) were alkylated and dehydrogenated to 21 and 22, respectively.

Funitremorgin B 1 is a tremorgenic toxin produced by the <u>Aspergillus</u>  $\frac{\text{fumigatus.}^{(1)}}{\text{coworkers}^{(2)}}$  The structure of 1 has been determined by Yamazaki and coworkers<sup>2</sup>) and 1 has been one of our synthetic target molecules.<sup>3</sup> While a few attemps to synthesize 1 has been reported<sup>4</sup>, no total synthesis has yet been published of any of the fumitremorgin family.

We have previously reported a new ß-carboline synthesis.<sup>5)</sup> Recent Harrison's publication<sup>6)</sup> prompted us to report our synthetic approach to optically active pentacyclic compounds of general form(13-18), as promissing intermediates leading to optically pure fumitremorgins and dehydrogenation of these compounds.

The Pictet-Spengler reaction has been employed to prepare 1,2,3,4tetrahydro- $\beta$ -carbolines.<sup>7)</sup> However, little is known about the racemization during the Pictet-Spengler reaction of L- or D-tryptophan ester with an aldehyde to the corresponding 1,3-cis- and trans-disubstituted-1,2,3,4tetrahydro- $\beta$ -carbolines.<sup>6,8)</sup> We now obtained optically active 1,3-cis- $\beta$ carbolines as a major isomer by the Pictet-Spengler reaction of L- and Dtryptophan methyl esters 2 and 6-methoxy-L-tryptophan methyl ester 3.

According to Cook's conditions,<sup>9)</sup> we first carried out the reaction of 2a and isovaleraldehyde in boiling benzene without or with TsOH and we obtained the cis isomer 4a and the trans isomer 5a in about same ratio which were, however, shown to be racemized to a greater extent by NMR spectrum and the  $[\alpha]_D$  value.<sup>10)</sup> We obtained 4a( $62\%, [\alpha]_D^{2^1} - 121^\circ$ )<sup>11),12</sup>) predominantly without significant racemization together with 5a( $33\%, [\alpha]_D^{2^5} + 51^\circ$ ),<sup>12)</sup> when the reaction of 2a with isovaleraldehyde in CH<sub>2</sub>Cl<sub>2</sub> in the presence of trifluoroacetic acid(TFA) (5.7 mole equivalents, r.t. 2 hr). Similar reaction of D-tryptophan methyl ester 2b with isovaleraldehyde gave 4b( 64\%,

 $[\alpha]_{D}^{16}$  +120.7°) as a major isomer and 5b( 34%,  $[\alpha]_{D}^{11}$  -52.4°). These results made us to examine the corresponding reaction of 6-methoxy-L-tryptophan methyl ester  $3^{13}$  with isovaleraldehyde in similar conditions. The reaction proceeded with predominant formation of 6( 53%, mp 151-152°,  $[\alpha]_{D}^{\circ}$  -122.3°),  $^{12}$  accompanied by the formation of 7( 30%, mp 151.5-153.5°,  $[\alpha]_{D}^{\circ}$  +58.4°).


Coupling reaction of 4 or 6 with proline was then accomplished by use of the acid chloride. Treatment of 4a with Z-L-prolyl chloride in  $CH_2Cl_2-Et_3N$  gave 8a(92%, mp 192.5-193.5°,  $[\alpha]_D^{12}-48.8°$ ). Deprotection of 8a(10% Pd/C, HCOONH<sub>4</sub>, MeOH, r.t.)<sup>16)</sup> was followed by spontaneous cyclization to give the parent pentacyclic compound 13(95%).<sup>17)</sup> Likewise, 4b and 5a could be converted into the corresponding pentacycles 16 via 8b and 14 via 9a, respectively. The dipeptide 11 was also obtained by the reaction of 6 with Z-L-prolyl chloride which was subjected to hydrogenolysis to give 15 (95%, mp 272-275°,  $[\alpha]_D^{3^2}-80.6°$ ). A simple two-step sequence has been developed to prepare 1,3-trans-oriented dipeptide 9a in stereoselective fashion; predominant formation of 9a(41%, mp 207-208°,  $[\alpha]_D^{13}-104.7°$ ) was achieved by the condensation of 2a with isovaleraldehyde ( $CH_2Cl_2$ , molecular sieves-4A, r.t, 12hr) followed by the acylation with Z-L-prolyl chloride. A similar series of reactions starting from 2b led to the formation of 17 via 9b.

Furthermore, the reaction of 4a with Z-D-prolyl chloride provided 10. Hydrogenolysis of 10 afforded 18( mp 264-266°,  $[\alpha]_D^{27}$ -95.1°). Comparison of the  $[\alpha]_D$  value of 18 with that of its enantiomer 16( mp 263.5-266°,  $[\alpha]_D^{25}$ +95.3°) suggests that little or no racemization occurred under these reaction conditions.


When the cis-diketopiperazine derivative 13 was treated with isopentyl bromide( 1.2 equiv. ) in DMF( r.t., 40 min.) in the presence of NaH( 1.1 equiv. ),  $19([\alpha]_D^{21}+112.0^\circ)$  was formed exclusively( 95% ), indicating that N-alkylation was accompanied by the simultaneous epimerization at C-12 position. Similar reaction of 15 provided  $20([\alpha]_D^{10}+125.9^\circ)$  in 98% yield.<sup>18</sup>)

Attempted dehydrogenation of pentacycles( 13, 15, and N-isopentyl derivative of 13 ) having cis diketopiperazine moiety with DDQ failed to give the corresponding 12,13-dehydro derivatives. Treatment of the 12-epimeric isomer, 19, with DDQ in  $CH_3CN-H_2O(7:3)$ , however, resulted in the formation of the expected dehydrogenated compound 21(  $\lambda$ max 236, 261, 367 nm;  $\nu$ max 1690, 1620 cm<sup>-1</sup>;  $\delta(CDCl_3)$  7.39( s,  $C_{13}$ -H ); m/z 419 M<sup>+</sup>;  $[\alpha]_D^{16}$ +145.8°) in 58% yield. Similally 20 underwent selective dehydrogenation to 22(  $\lambda$ max 219, 236sh, 268, 298, 376 nm;  $\delta(CDCl_3)$  7.33( s,  $C_{13}$ -H ); m/z (%) 449(14) M<sup>+</sup>, 392(100),  $[\alpha]_D^{16}$ +137.4°) in 62% yield.


The present study provides clear guidelines for the synthesis of pentacyclic intermediates to fumitremorgines. Our extension and application of these results toward the total synthesis of 1 will be reported.



- 2a, R=H, L-Tryptophan
- b, R=H, D-Tryptophan
- 3, R=OMe, L−Tryptophan



	K. K					
4a - 11						
	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>
4a	i-Bu	н	н	CO <sub>2</sub> Me	н	н
4ь	н	i-Bu	н	н	CO2Me	н
<u>5a</u>	н	i-Bu	н	CO <sub>2</sub> Me	<u>н</u>	Н
<u>5</u> Ъ	i-Bu	н	н	н	_CO2Me	H
6	i-Bu	н	н	CO2Me	н	OMe
Z	н	i-Bu	н	CO <sub>2</sub> Me	н	OMe
<u>8a</u>	i-Bu	н	Z-L-Pro	CO_2Me	Н	н
<u>8</u> b	н	i-Bu	Z-L-Pro	н	CO <sub>2</sub> Me	н
<u>9a</u>	н	i-Bu	Z-L-Pro	CO <sub>2</sub> Me	_н	H
<u>9</u> Ъ	i-Bu	н	Z-L-Pro	н_ ,	CO <sub>2</sub> Me	н
10	i <u>-B</u> u	Н	Z-D-Pro	CO <sub>2</sub> Me	н	н
11	i-Bu	Н	Z-L-Pro	CO2Me	н	OMe



Acknowledegement The financial support of this research by Grant-in-Aid for Scientific Research given from the Ministry of Education, Science, and Culture is greatly appreciated.

References and Notes.

- 1. M. Yamazaki, S. Suzuki, and K. Miyaki, Chem. Pharm. Bull., 19, 1739 (1971).
- a) M. Yamazaki, K. Sasago, and K. Miyaki, <u>J.C.S., Chem.Comm.</u>, 1974, 408
   b) M. Yamazaki, K. Suzuki, H. Fujimoto, T. Akiyama, U. Sankawa, and Y. Iitaka, Chem.Pharm.Bull., 28, 861 (1980).
- 3. A part of our work has been reported in The 28th Sympodium on the Chemistry of Natural Products (Hiroshima)(1985), Abstr. p208.
- 4. a) Y. Oikawa, T. Yoshioka, and O. Yonemitsu, The 21th Sympodium on the Chemistry of Natural Products (Sapporo)(1978), Abstr. p22; b) D.M. Harrison, <u>Tetrahedron Lett.</u>, 22, 2501 (1981); c) S. Nakatsuka, K. Teranishi, and T. Goto, The 50th. Annual Meeting of the Chemical Society of Japan (Tokyo)(1985) Abstr. p 111.
- 5. M. Nakagawa, K. Matsuki, and T. Hino, <u>Tetrahedron Lett</u>., 24, 2171 (1983).
- 6. D.M. Harrison and R.B. Sharma, Tetrahedron Lett., 27, 521 (1986).
- 7. Recent Review : F. Ungemach and J.M. Cook, Heterocycles, 9, 1089 (1978).
- a) A. Brossi, A. Focella, and S. Teitel, <u>J.Med.Chem</u>., 16, 418 (1973); b)
   E. Yamanaka, N. Shibata, K. Kubota, and S. Sakai, The 105 Annual Meeting on the Phamaceutical Society of Japan (1985), Abstr. p564.
- 9. a) D. Soerens, J. Sandrin, F. Ungemach, P. Mokry, S.G. Wu, E. Yamanaka, L. Hutchins, M.Di Pierri, and J.M. Cook, <u>J.Org.Chem</u>., 44, 535 (1979);
  b) M. Jawdosiuk and J.M. Cook, <u>J.Org.Chem</u>., 49, 2699 (1984).
- 10. 4a : 21.7% e.e.( without TsOH ), 80.2% e.e.( with TsOH ).
- 11. All new compounds gave IR, UV, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, and Mass spectra that are consistent with the structures assigned. Crystalline compounds gave satisfactory elemental analysis. Optical rotations were taken in MeOH.
- 12. The NMR spectrum using the chiral shift reagent( tris(3-heptafluorobutyryl-d-camphorato)europium(III)) showed the absence of the other enantiomer.
- 13. The optically active 6-methoxytryptophan ester was synthesized according to our method  $^{14}$  and the reference  $^{15}$ .
- M. Taniguchi, T. Anjiki, M. Nakagawa, and T. Hino, <u>Chem.Pharm.Bull</u>., 32, 2544 (1984).
- 15. K. Irie, A. Ishida, and T. Nakamura, Chem.Pharm.Bull., 32, 2126 (1984).
- 16. M.K. Anwer and A.F. Spatola, Synthesis, 1980, 929.
- 17. 13, mp 289-290°,  $[\alpha]_{D}^{1}$ -76.3°; vmax (KBr) 3260 (NH), 1665 (CO) cm<sup>-1</sup>.
- 18. 20, colorless amorphous powder;  $\lambda max$  (EtOH) nm 230, 277, 296, 307sh; vmax (KBr) 1660 cm<sup>-1</sup>; <sup>1</sup>H-NMR  $\delta$ (CDCl<sub>3</sub>) 0.94, 1.01, 1.02, and 1.15(12H,d, J= 6.3 Hz, Me), 1.5-2.15(9H,m, C<sub>7</sub>-H<sub>A</sub>H<sub>B</sub>-CH<sub>2</sub>, Me<sub>2</sub>CHCH<sub>2</sub>), 2.50(1H,m, C<sub>7</sub>H<sub>A</sub>H<sub>B</sub>), 2.91 (1H,dd,J=15.0, 12.4Hz, C<sub>13</sub>-H<sub>A</sub>H<sub>B</sub>), 3.29(1H,dd,J=15.5, 4.6Hz, C<sub>13</sub>H<sub>A</sub>H<sub>B</sub>), 3.60 (1H,m, N<sub>10</sub>-CH<sub>A</sub>H<sub>B</sub>), 3.80(1H,m, N<sub>10</sub>-CH<sub>A</sub>H<sub>B</sub>), 3.88(3H,s, OMe), 3.90-4.15(3H, m, N<sub>1</sub>-CH<sub>2</sub>, C<sub>6</sub>-H), 4.46(1H,dd,J=12.0, 4.5Hz, C<sub>12</sub>-H), 5.88(1H,d,J=10.2Hz, C<sub>3</sub>-H), 6.75-6.80(2H,m, C<sub>17</sub>-H, C<sub>19</sub>-H), 7.30(1H,d,J=8.9Hz, C<sub>16</sub>-H); Exact mass : calcd. for C<sub>27</sub>H<sub>37</sub>N<sub>3</sub>O<sub>3</sub> 451.2837. Found, 451.2828.
- The reaction mixture was treated with 5% HCl before work-up. (Received in Japan 1 May 1986)